Novo Nordisk said it will now move ahead with a phase 3 programme for both versions of the drug in adults with type 2 ...

At Frontiers Health 2025, we spoke with Meri Beckwith (Lindus Health), Daniel Diezi (Gerresheimer), and David Benshoof Klein ...

Reimbursement authority NICE has ruled that London-based Autolus' Aucatzyl (obecabtagene autoleucel or obe-cel) can be used ...

In a boost for the UK life sciences sector, a new life sciences hub located at Barts Health NHS Trust in London has opened ...

Dual glucagon (GCG) and GLP-1 agonist mazdutide is already approved for both type 2 diabetes and obesity in China at doses ...

Graphite Digital’s study of 100 senior pharma leaders across Europe and North America earlier this year investigated ...

The new intrathecal formulation means the one-shot gene therapy is now available to all SMA patients, regardless of their age, and could free them from having to take regular, lifelong SMA treatments ...

Phil Davey is the General Manager at Alnylam for the UK, Ireland, the Nordics, and Canada. With over 20 years in the ...

Join the West Coast's premier pharma and biotech gathering, the 10th Tumor Models Summit San Francisco, where innovation ...

In Evaluate’s recently released annual World Preview Report, including updated global pharmaceutical market projections ...

The Prescription Medicines Code of Practice Authority (PMCPA) has ruled that Angelini has fallen short of its standards by allowing a speaker at a 2023 meeting to disparage the EMA, questioning its ...

Novo Nordisk has just released the topline findings from two eagerly anticipated phase 3 trials of its oral formulation of ...